Taranabant CB1 Receptor Inverse Agonist for Management of Obe
Key Data:
Drug (brand/generic)
Taranabant
Company/licensee
Merck & Co
Therapy class
Selective cannabinoid-1 (CB1) receptor inverse agonist
Product description
Binds to the CB1 endocannabinoid receptor
Current indication
Treatment of obesity in combination with dietary control
Market sector
Nutrition
Development status
Phase III
